H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $500.00.
Patrick Trucchio has given his Buy rating due to a combination of factors including Alnylam Pharma’s strong commercial momentum and promising pipeline. The company’s lead product, AMVUTTRA, has shown robust uptake in treating hereditary ATTR with polyneuropathy and is gaining traction in ATTR with cardiomyopathy, contributing to a significant year-over-year revenue growth.
Furthermore, Alnylam’s reaffirmation of its 2025 financial guidance, which projects substantial product revenues and sustainable non-GAAP operating profitability, underscores its strategic execution. The anticipated initiation of several late-stage programs in 2025, including those for nucresiran, zilebesiran, and elebsiran, positions Alnylam to deliver significant clinical, commercial, and financial catalysts in the near future. These factors collectively support the Buy rating and the $500 price target for ALNY.
In another report released on May 2, Chardan Capital also maintained a Buy rating on the stock with a $325.00 price target.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.